Daxor Corporation (DXR) Stock

Daxor Corporation (DXR) is a Healthcare stock trading at $10.41 (as of 2026-07-23), with a market capitalization of $43.68M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Understand Daxor Corporation: how it makes money

Daxor Corporation develops and markets BVA-100, a blood volume analyzer technology used for blood volume testing, to provide objective quantification of blood volume status and composition for clinical decision support across a range of medical and surgical conditions.

The company’s profit model is driven by commercialization of its BVA-100 blood volume measurement technology, since revenue depends on clinical adoption of the analyzer’s diagnostic blood testing approach and the cost to develop, market, and run that device business.

Business quality (Weak): Limited disclosure here, no official reportable segments or operational KPIs provided, and the only financial details shown are gross margin and operating margin for 2011-09-30.

Bull case

  • Objective blood volume measurement focus: Daxor’s BVA-100 is designed to provide safe, accurate, objective quantification of blood volume status and composition compared with patient-specific norms.
  • Broad clinical application framing: The technology is described as used across a broad range of medical and surgical conditions, which can support wider market opportunity if adoption continues.

Bear case

  • Operating losses: For the period 2011-09-30, operating margin is reported as -369.9%, indicating operating losses.
  • No visibility into segment or operating drivers: With no reportable segments or operational KPIs provided, it is harder to pinpoint what specifically drives performance, growth, or cost changes.
Valuation — source: SEC EDGAR (first-party)
Price$10.41
Market Cap$43.68M
Price / Book1.21
Price / Sales28.73
FCF Yield-40.2%
DCF Value (model)$6.40
DCF Upside vs Price-38.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.45M
Net Margin-496.8%
Revenue Growth (YoY)-74.4%
EPS Growth (YoY)-78.2%
FCF Growth (YoY)-152.2%
Financial Health — source: SEC EDGAR
Altman Z-Score1.18 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderTHOMPSON SIEGEL & WALMSLEY LLC ($2.25M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical - Instruments & Supplies
CEOMichael Richard Feldschuh
Employees37
CountryUS
IPO Date1983-07-25

Related Companies (Business model: Closed-End Fund; 8 closest by market cap; US-domiciled)

  • Pearl Diver Credit Company Inc. (PDCC)
  • Advanced Flower Capital Inc. (AFCG)
  • LanzaTech Global, Inc. (LNZA)
  • Launchpad Cadenza Acquisition Corp I Class A Ordinary Share (LPCV)
  • Laird Superfood, Inc. (LSF)
  • Manhattan Bridge Capital, Inc. (LOAN)
  • OFS Capital Corporation (OFS)
  • Rand Capital Corporation (RAND)
DXR earnings history · DXR institutional & insider holders · DXR KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-23.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.